{"transactions":[{"id":3005313,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":145900,"kind":"organization","name":"HealthCap VIII, L.P.","position":1,"cik":"0001783281","reported_name":"HealthCap VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Series B Preferred Stock","published_at":"2020-10-16T16:08:37.000Z","date":"2020-10-14","kind":"exercise","acquired":false,"shares":11666666,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B Preferred Stock automatically converted into 0.152881822351322 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering on October 14, 2020 (on an adjusted basis, after giving effect to the 1-for-6.541 reverse stock split of the common stock effected by the Issuer on October 2, 2020). The shares have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B Preferred Stock automatically converted into 0.152881822351322 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering on October 14, 2020 (on an adjusted basis, after giving effect to the 1-for-6.541 reverse stock split of the common stock effected by the Issuer on October 2, 2020). The shares have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B Preferred Stock automatically converted into 0.152881822351322 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering on October 14, 2020 (on an adjusted basis, after giving effect to the 1-for-6.541 reverse stock split of the common stock effected by the Issuer on October 2, 2020). The shares have no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Each share of Series B Preferred Stock automatically converted into 0.152881822351322 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering on October 14, 2020 (on an adjusted basis, after giving effect to the 1-for-6.541 reverse stock split of the common stock effected by the Issuer on October 2, 2020). The shares have no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are directly held by HealthCap VIII, L.P. (\"HCLP\"). HealthCap VIII GP SA (\"HCSA\") is the sole general partner of HCLP and has voting and investment control over such shares held by HCLP. Jonas Hansson, a Director of the Issuer, has an indirect interest in HCSA and is an employee of HealthCap VIII Advisor AB. Each of the General Partner and Mr. Hansson disclaims beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that the General Partner or Mr. Hansson is the beneficial owner of such shares."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1783621},"source":{"system":"sec-edgar","filing":"0001209191-20-055012","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000120919120055012/doc4.xml","form_type":"4"}},{"id":3005312,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":145900,"kind":"organization","name":"HealthCap VIII, L.P.","position":1,"cik":"0001783281","reported_name":"HealthCap VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Common Stock","published_at":"2020-10-16T16:08:37.000Z","date":"2020-10-14","kind":"purchase","acquired":true,"shares":250000,"price":15,"value":3750000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The shares were purchased in the Issuer's initial public offering."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are directly held by HealthCap VIII, L.P. (\"HCLP\"). HealthCap VIII GP SA (\"HCSA\") is the sole general partner of HCLP and has voting and investment control over such shares held by HCLP. Jonas Hansson, a Director of the Issuer, has an indirect interest in HCSA and is an employee of HealthCap VIII Advisor AB. Each of the General Partner and Mr. Hansson disclaims beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that the General Partner or Mr. Hansson is the beneficial owner of such shares."}],"balance_after":2033621,"source":{"system":"sec-edgar","filing":"0001209191-20-055012","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000120919120055012/doc4.xml","form_type":"4"}},{"id":3005311,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":145900,"kind":"organization","name":"HealthCap VIII, L.P.","position":1,"cik":"0001783281","reported_name":"HealthCap VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Common Stock","published_at":"2020-10-16T16:08:37.000Z","date":"2020-10-14","kind":"exercise","acquired":true,"shares":1783621,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Preferred Stock automatically converted into 0.152881822351322 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering on October 14, 2020 (on an adjusted basis, after giving effect to the 1-for-6.541 reverse stock split of the common stock effected by the Issuer on October 2, 2020). The shares have no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are directly held by HealthCap VIII, L.P. (\"HCLP\"). HealthCap VIII GP SA (\"HCSA\") is the sole general partner of HCLP and has voting and investment control over such shares held by HCLP. Jonas Hansson, a Director of the Issuer, has an indirect interest in HCSA and is an employee of HealthCap VIII Advisor AB. Each of the General Partner and Mr. Hansson disclaims beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that the General Partner or Mr. Hansson is the beneficial owner of such shares."}],"balance_after":1783621,"source":{"system":"sec-edgar","filing":"0001209191-20-055012","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000120919120055012/doc4.xml","form_type":"4"}}]}